Last updated on November 2017

Celgene Lymphoma Robust

Brief description of study

Celgene Lymphoma Robust

Detailed Study Description

Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2 CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects with Previously Untreated Activated B-Cell Type Diffuse Large B-Cell Lymphoma

Clinical Study Identifier: TX9038


Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Columbus Regional Research institute

Columbus Regional Research institute
Columbus, GA USA
  Connect »